NCT00904670View on ClinicalTrials.gov

Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Quillivant Oral Suspension XR

Oral Suspension 25mg/5mL; 20-60 mg/day

DRUG

Placebo

Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day

DRUG

Placebo

Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.

Trial Locations (2)

89128

Center for Psychiatry and Behavioral Medicine, Incorporated, Las Vegas

92612

UC Irvine Child Development Center, Irvine

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00904670 - Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) | Biotech Hunter | Biotech Hunter